The complete list of business models in the femtech market
Last updated: 13 March 2026
Download our beautiful pitch about the femtech market
In our femtech market deck, you will find everything you need to understand the market
The femtech market has grown into one of the most structurally diverse segments in digital health, spanning consumer apps, employer benefits, diagnostics, care delivery, and biotech.
This page tracks the main business models used by femtech startups, with regular updates as new models emerge and existing ones evolve.
Each model is evaluated on scalability, margin potential, defensibility, and capital intensity, so investors and founders can quickly compare the structural economics of each approach.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
A quick summary table
| Metric | Value |
|---|---|
| Total femtech business models mapped | 32 |
| Highest scalability score | 10 (cycle-tracking consumer apps) |
| Most defensible femtech categories | Therapeutics, provider AI, IVF lab infrastructure (scores 8–10) |
| Top femtech revenue models | Subscription, outcome-based, transaction fee |
| Dominant femtech sales motions | Enterprise sales, product-led, partnerships |
| Capital intensity of top-ranked models | Mostly low to medium |
| Best scalability + defensibility combo | Employer and payer-funded femtech platforms (8 / 7–8) |
| Femtech models with highest margin potential | Therapeutics (10), provider SaaS (9), consumer apps (9) |
| Most capital-intensive femtech models | Clinic networks, lab automation, therapeutics pipelines |
| Femtech customer segments | Consumers, employers, health plans, fertility clinics, providers |
| Weakest defensibility in femtech | Consumer wellness commerce, fertility coaching (scores 4) |
| Strongest femtech venture zones | Employer ROI platforms, provider infrastructure, diagnostic-to-treatment loops |
In our femtech market deck, we provide the data and the context to understand it
All the business models in the femtech market
Here is a table that maps the main business models in the femtech market, highlighting how they differ in scalability, margins, defensibility, capital intensity, and monetization approach.
| # | Business Model | Description | Example Companies | Scalability | Margin Potential | Defensibility | Capital Intensity | Category | Who Pays | Customer Segment | Revenue Model | Pricing Metric | Sales Motion | Key Strengths | Key Risks | Investor Perspective |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cycle-tracking subscription app | Consumer app monetizing tracking, personalization, and premium reproductive-health features. | Flo Health, Clue, Hormona | 10 | 9 | 5 | Low | Consumer App | Consumers | Consumers | Subscription | Per user / month | Product-led | Global reach and software-like margins | Weak retention and monetization pressure | Huge TAM, but conversion and retention determine value |
| 2 | Regulated digital contraception subscription | Regulated contraception software monetized through subscriptions, sometimes bundled with hardware. | Natural Cycles, Daysy, Lady Cycle | 9 | 9 | 8 | Low | Consumer App | Consumers | Consumers | Subscription | Per user / month | Product-led | Regulation and efficacy create stronger consumer software moat | Regulatory and reputational sensitivity | Best-in-class consumer app if trust and retention hold |
| 3 | Employer family-health benefits platform | Employers buy broad family-health access, navigation, coordination, and virtual support. | Maven Clinic, Stork Club, Peppy, Fertifa, Apryl | 8 | 8 | 7 | Medium | Platform | Employers and health plans | Enterprises | Subscription | Per employee / month | Enterprise sales | Budget access and recurring multi-life contracts | ROI scrutiny and budget pressure | Strong recurring revenue if benefit becomes strategic spend |
| 4 | Employer fertility navigation benefit | Employers pay for fertility navigation, support, financing, and clinic steerage. | Future Family, Apryl, Fertifa, Stork Club, Univfy | 8 | 7 | 7 | Medium | Platform | Employers | Enterprises | Subscription | Per member / month | Enterprise sales | Acute pain point with measurable spend optimization | Crowding and navigation-only commoditization | Attractive if vendor controls critical fertility workflow |
| 5 | Health-plan maternity care management | Payers buy maternal support programs to improve outcomes and reduce costs. | Pomelo Care, Wildflower Health, Babyscripts, Mahmee, Delfina | 8 | 7 | 8 | Medium | Services | Health plans | Institutions | Outcome-based | Per member / year | Enterprise sales | Large contracts and outcomes-linked embedded workflows | Long sales and implementation complexity | Best when renewals and savings evidence are strong |
| 6 | Value-based maternal health platform | Platform shares accountability for maternity outcomes and total cost reduction. | Pomelo Care, Visana Health, Wildflower Health, Cayaba Care | 8 | 7 | 8 | High | Services | Health plans | Institutions | Outcome-based | Shared savings contract | Enterprise sales | Larger economic pool than navigation alone | Execution risk in proving savings | High upside if outcomes persist at scale |
| 7 | Fertility financing and risk-sharing | Financing layer eases treatment payments through underwriting and outcome-linked plans. | Future Family, Gaia Fertility, Univfy | 8 | 8 | 8 | Medium | Fintech | Patients, employers, clinics | Consumers | Transaction fee | Per financed cycle | Partnerships | Asset-light reach across clinics with strong data leverage | Credit losses and regulatory scrutiny | Compelling if proprietary risk data compounds underwriting edge |
| 8 | Hardware plus recurring consumables | Device adoption drives recurring strip or cartridge replenishment revenue. | Inito, Oova, Proov, Inne | 8 | 7 | 7 | Medium | Hardware | Consumers | Consumers | Transaction fee | Per consumable reorder | Self-serve | Recurring replenishment improves hardware economics materially | Inventory complexity and journey-limited demand | Reorder behavior matters far more than device sales |
| 9 | At-home reproductive diagnostics kits | Home reproductive tests generate revenue from kits and optional follow-up care. | Evvy, Hertility Health, Teal Health, Proov, Oova | 8 | 7 | 7 | Medium | Data | Consumers and insurers | Consumers | Transaction fee | Per kit | Self-serve | Convenience plus centralized lab economics | Episodic demand without repeat loop | Valuable when testing opens broader care relationship |
| 10 | D2C diagnostics plus treatment loop | Testing leads into treatment, coaching, prescriptions, or ongoing care. | Evvy, Hertility Health, Teal Health, Daye, Aster Health | 8 | 8 | 8 | Medium | Data | Consumers | Consumers | Subscription | Per care program | Product-led | Higher LTV from owned diagnostic-to-treatment pathway | Clinical complexity and regulatory exposure | One of the strongest consumer healthcare loops in femtech |
| 11 | Telepharmacy reproductive care | Online consultations and prescribing paired with medication fulfillment and delivery. | Twentyeight Health, Hey Jane, Alpha Medical, TBD Health | 8 | 7 | 6 | Medium | Services | Consumers and insurers | Consumers | Subscription | Per prescription refill | Product-led | Recurring needs and standardized fulfillment economics | Pharmacy margin compression and regulation | Durable if refill behavior and channels stay resilient |
| 12 | Women's diagnostics commercialization platform | Novel tests monetize through lab volume, reimbursement, and provider adoption. | NextGen Jane, Mercy BioAnalytics, PinkDx, AOA Dx, Juno Bio | 8 | 8 | 8 | High | Data | Providers and labs | Institutions | Licensing | Per test | Enterprise sales | Proprietary biomarkers can scale into attractive lab economics | Adoption and reimbursement take time | Strong upside if clinical utility converts into standard testing |
| 13 | Employer screening hardware-as-a-service | Screening hardware deployed via recurring subscription or usage-based contracts. | Salva Health, MobileODT, iSono Health | 8 | 6 | 7 | High | Hardware | Providers and public programs | Institutions | Usage-based | Per device / month | Partnerships | Lower upfront friction unlocks recurring device deployment | Working-capital burden can overwhelm returns | Smart structure only when usage density supports payback |
| 14 | Consumer women's wellness commerce | D2C wellness products monetize through repeat purchases and subscriptions. | Bird&Be, Daye, Gynoveda, Proov | 8 | 7 | 4 | Low | Consumer App | Consumers | Consumers | Subscription | Per order | Self-serve | Strong gross margins and broad consumer appeal | Brutal CAC and weak defensibility | Brand alone rarely supports venture-scale durable returns |
| 15 | Consumer fertility hardware subscription | Connected fertility device drives recurring app or analytics subscriptions. | Ava, Lady Technologies, Inne | 7 | 6 | 6 | Medium | Hardware | Consumers | Consumers | Subscription | Per device + subscription | Self-serve | Hardware commitment can improve engagement and LTV | Hardware complexity and copycat risk | Good if software becomes meaningful profit layer |
| 16 | Provider ultrasound and screening AI SaaS | Providers buy AI workflow, analysis, and risk-scoring software. | Sonio, Vara, Clairity, Ataraxis AI | 7 | 9 | 9 | Medium | SaaS | Providers | Enterprises | Subscription | Per site / month | Enterprise sales | Software margins with regulatory and workflow lock-in | Slow validation-driven enterprise adoption | One of the cleanest femtech models for software investors |
| 17 | IVF clinic workflow software | Fertility clinics buy workflow, analytics, and decision-support software. | Alife Health, AIVF, Univfy | 7 | 8 | 8 | Medium | SaaS | Fertility clinics | Enterprises | Subscription | Per clinic / month | Inside sales | High-value niche with sticky embedded workflows | Narrow market and proof burden | Strong niche SaaS if product becomes operationally essential |
| 18 | Women's health therapeutics pipeline | Drug developers monetize via approvals, partnerships, milestones, or launches. | Freya Biosciences, ReproNovo, Gesynta Pharma, Comanche Biopharma | 7 | 10 | 10 | High | Biotech | Pharma partners and insurers | Institutions | Licensing | Per milestone | Business development | Massive upside from patents and global indications | Binary clinical and regulatory risk | Extraordinary upside, but not comparable to operating software businesses |
| 19 | Insurance-based virtual women's clinic | Telehealth clinic delivers reimbursed women's specialty care through insurance. | Midi Health, Allara Health, Visana Health, Alpha Medical | 6 | 6 | 7 | Medium | Services | Insurers | Consumers | Usage-based | Per visit | Partnerships | Broader access with recurring specialty care demand | Clinician supply and reimbursement complexity | Attractive if utilization and contribution margins improve steadily |
| 20 | Cash-pay specialty telehealth membership | Consumers pay directly for ongoing virtual specialty women's healthcare. | Evernow, Alloy Women's Health, Hey Jane, TBD Health | 6 | 7 | 5 | Medium | Services | Consumers | Consumers | Subscription | Per member / month | Product-led | Transparent pricing and recurring treatment potential | CAC pressure and lower willingness to pay | Works best where recurring medication boosts retention |
| 21 | Fertility clinic plus benefits hybrid | Employer benefits layer funnels patients into owned fertility care delivery. | Kindbody, Future Family, Apryl | 6 | 7 | 9 | High | Platform | Employers and patients | Enterprises | Subscription | Per employee / month | Enterprise sales | Captures multiple value layers across journey | Operational complexity across clinics and benefits | Powerful integrated model when referral capture stays strong |
| 22 | Modern maternity clinic network | Modern prenatal and postpartum clinics monetize through reimbursement and support services. | Oula, Millie, Diana Health, Kindbody | 5 | 5 | 7 | High | Services | Insurers and patients | Consumers | Usage-based | Per visit | Local partnerships | Strong NPS and referral loops in high-value care | Geography and provider capacity constrain growth | Attractive if site playbook and outcomes replicate reliably |
| 23 | Multi-site women's practice management platform | Aggregates women's practices under shared operations, infrastructure, and technology. | Advantia Health, Tia, Diana Health | 5 | 6 | 8 | High | Services | Insurers and patients | Consumers | Usage-based | Per visit | M&A-led sales | Operational leverage across fragmented specialty practices | Integration risk and capital-heavy expansion | Can become scaled platform, or mediocre operator, fast |
| 24 | Lower-cost at-home fertility treatment | Consumer kits provide affordable fertility treatment outside traditional clinics. | Bea Fertility, Mosie Baby, Frida Fertility | 5 | 6 | 5 | Medium | Consumer App | Consumers | Consumers | Transaction fee | Per treatment kit | Self-serve | Clear affordability wedge versus clinic alternatives | Narrow scope and modest repeat behavior | Good wedge only if expanded into broader journey |
| 25 | Maternal support services platform | Tech-enabled maternal services coordinate doulas, lactation, therapy, and nutrition. | Partum Health, Mahmee, Cayaba Care, Chiyo | 5 | 5 | 6 | Medium | Services | Consumers, employers, health plans | Consumers | Usage-based | Per care package | Partnerships | Trusted support improves outcomes and customer satisfaction | Labor intensity constrains software-like scaling | Better economics when attached to payer or employer budgets |
| 26 | Prescription pelvic-health device | Clinically recommended therapeutic device sold through providers or patients. | Axena Health, Renovia, Uresta, Pelvital, Materna Medical | 5 | 7 | 8 | High | Hardware | Providers and patients | Consumers | Per device | Per device | Provider-led | Clinical validation and reimbursement can build durable moat | Slow adoption and education burden | Strong if device enters standard care pathways |
| 27 | Marketplace for egg donation matching | Marketplace connects intended parents and donors, monetizing matching and coordination. | Cofertility, Donor Nexus, MyEggBank | 5 | 6 | 6 | Medium | Marketplace | Intended parents | Consumers | Commission | Per match | Partnerships | High-value transactions in fragmented emotional category | Liquidity and service burden challenges | Works only if trusted liquidity becomes self-reinforcing |
| 28 | Hybrid women's primary care clinics | Physical clinics plus digital access deliver integrated women's primary care. | Tia, HerMD, Iron Health, Plenna | 4 | 5 | 7 | High | Services | Insurers and patients | Consumers | Usage-based | Per visit | Local expansion | Deep care ownership and cross-sell opportunities | Operational complexity and local expansion difficulty | Worth backing only with excellent clinic unit economics |
| 29 | IVF lab automation infrastructure | Labs buy robotics, cryostorage, and automation with software and service layers. | Overture Life, TMRW Life Sciences, Conceivable Life Sciences | 4 | 6 | 9 | High | Hardware | IVF clinics | Enterprises | Per device | Per lab system | Enterprise sales | Mission-critical infrastructure with long-term workflow lock-in | Long sales and implementation burden | Strong moat, but slower path and heavy capital needs |
| 30 | Provider imaging and procedural devices | Providers buy regulated devices for imaging, screening, or procedure workflows. | MobileODT, illumigyn, iSono Health, Nua Surgical, Salva Health | 4 | 6 | 8 | High | Hardware | Providers and hospitals | Enterprises | Per device | Per device | Enterprise sales | IP and regulatory barriers can create durable device moat | Procurement cycles and reimbursement dependence | Good medtech upside if device enters standard workflows |
| 31 | Consumer maternal device brand | Pregnancy and postpartum hardware monetized through device and accessory sales. | Elvie, Willow, Perifit, Fizimed | 4 | 5 | 5 | High | Hardware | Consumers and insurers | Consumers | Per device | Per device | Self-serve | Strong consumer need with channel diversification potential | Recalls, commoditization, and expensive brand spend | Best when insurance and accessories reduce D2C dependence |
| 32 | Fertility coaching and support subscription | Consumers pay for coaching, education, community, and conception support. | Conceive, Peanut, Fertility Circle | 4 | 8 | 4 | Low | Consumer App | Consumers | Consumers | Subscription | Per member / month | Self-serve | Fast launch and high gross margin potential | Soft moat and limited monetization depth | Best used as funnel into higher-value products |
In our femtech market deck, we will give you useful market maps and grids
Key insights about business models in the femtech market
Insights
- Employer and payer-funded femtech platforms consistently score scalability 8 with defensibility 7 to 8, suggesting that who controls the budget is one of the clearest predictors of venture-quality economics in women's health.
- Provider AI and femtech SaaS pair margin potential of 9 with defensibility of 8 to 9, making them arguably better long-term investments than faster-growing consumer apps, despite narrower markets.
- The diagnostics-to-treatment loop scores one point higher on both margins and defensibility than standalone femtech diagnostic kits, confirming that testing only becomes durable once it opens a recurring care relationship.
- Fertility financing scores 8 on scalability, margins, and defensibility without owning a single clinic, placing it among the most attractive non-software models in the entire femtech landscape.
- Consumer wellness commerce in femtech scores defensibility of just 4, making it one of the easiest categories to overvalue on brand momentum and gross margin optics alone.
- Nearly all high-capital femtech models rank in the bottom half on scalability, confirming that capital intensity is the clearest structural dividing line in the market.
- Fertility remains the most economically diverse segment in femtech, spanning at least eight distinct business models, which means "fertility exposure" alone says almost nothing about business quality.
In our femtech market deck, we identify repeatable patterns you can use if you’re building in this market
A few words about our methodology
This table maps the main business models used by startups in the femtech market.
To build it, we first analyzed the leading femtech startups and examined how each one actually generates revenue.
We then grouped similar approaches into clear business model categories. The goal was to capture meaningful differences without creating an overwhelming number of models.
Each femtech business model is evaluated across four structural dimensions: scalability, margin potential, defensibility, and capital intensity.
Scalability measures how easily the model can grow without proportional increases in cost. Margin potential reflects the long-term gross margin typically achievable once the model reaches maturity.
Defensibility captures how sustainable the competitive advantage can be over time, considering factors like switching costs, network effects, or proprietary data.
Capital intensity indicates how much upfront investment is usually required to build and scale the model.
For scalability, margin potential, and defensibility, scores range from 0 to 10. Lower scores indicate structural limitations, while scores above 7 generally signal strong economic potential.
These scores are not precise forecasts. They reflect the typical economics we observe across femtech companies using that model.
This framework is part of the broader research behind our report covering the femtech market, where we analyze the femtech ecosystem in much more detail.
If you want to better understand the femtech ecosystem, you can also check our ranking of femtech startups with the most fundraising and the list of femtech startups with the biggest valuations.
If you want more detail about our femtech business model analysis or about a specific company in the market, feel free to contact us. We will gladly explain.
In our femtech market deck, we identify repeatable patterns you can use if you’re building in this market
Related blog posts
- The most recent news in the femtech market
- The latest funding news in the femtech market
- The latest developments in the femtech market
- How funding activity has evolved in the femtech market
- What are the key fundraising trends in the femtech market?
